Cagrilintide and Semaglutide: Two Hormone Families, Two Receptor Systems

Viewing cagrilintide and semaglutide as two competing versions of the same concept misunderstands both. They derive from different hormones and bind different receptors: cagrilintide is an extended-action amylin analogue acting on calcitonin receptor and amylin receptor complexes, while semaglutide is a fatty-acid-modified GLP-1 analogue acting on the GLP-1 receptor. Researchers therefore tend to treat them as complementary tools, and the combination studied under the name CagriSema was built precisely on the fact that the two pathways do not overlap. Comparing cagrilintide with semaglutide really comes down to which satiety pathway your experimental system can actually measure.

Both are supplied as sealed freeze-dried powder, each lot with its own HPLC certificate — cagrilintide in 5 mg and 10 mg vials, semaglutide in 5, 10, 20, 30 or 50 mg vials — and both are listed in our GLP-1 and incretin peptide category. They are research chemicals for laboratory use and are not medicines.

Two distinct hormones, not two versions of one

Amylin itself is a 37-amino-acid peptide that pancreatic beta cells co-secrete with insulin. It signals through receptor complexes formed when the calcitonin receptor associates with a receptor-activity-modifying protein, producing the AMY1, AMY2 and AMY3 subtypes, and research associates it with meal-ending satiety and delayed emptying of the stomach. Native human amylin is notoriously awkward in the lab because it forms amyloid fibrils once dissolved, so it makes a poor reagent. Cagrilintide solves this on two fronts: amino-acid substitutions that prevent fibrils, and a fatty side chain that binds albumin reversibly and greatly extends its duration of action. The detailed structure is described in what is cagrilintide.

Semaglutide originates from the opposite side of the gut–pancreas axis. It is based on GLP-1(7-37), the incretin secreted by the intestine in response to food, with an Aib substitution that blocks cleavage by dipeptidyl peptidase-4 and a C18 fatty diacid attached for extended action. Its only target is the GLP-1 receptor, and comparative panels routinely use it as the benchmark agonist at that receptor.

Why researchers combine the two pathways

The two compounds are studied together because the brain areas they reach coincide even though their receptors are unrelated. Amylin receptor activity has been localised above all to the area postrema and adjacent hindbrain nuclei; GLP-1 receptor activity has been reported in the same hindbrain territory and in hypothalamic networks too. When different receptors converge on shared circuitry, pairing an amylin analogue with an incretin agonist becomes a way to ask whether two separate satiety signals sum, amplify each other, or overlap. That rationale is spelled out in our CagriSema and amylin analogs briefing, and it explains why a ready-made semaglutide plus cagrilintide combination is offered for research in the first place.

Designing an amylin versus incretin experiment

1. Confirm the receptors present before anything else: an AMY subtype requires the calcitonin receptor plus the matching RAMP, so cells with the calcitonin receptor and no RAMP do not model amylin signalling.
2. Plan concentrations in molar units: 4409.07 versus 4113.58 g/mol is a gap of roughly 7%, large enough to distort any comparison matched by mass.
3. Test each molecule on its own before testing them together, because a combination arm lacking both mono-arms cannot separate additivity from redundancy.
4. When stomach emptying is measured, note that both pathways slow it, so allow a longer observation window for the combined arm than for either compound alone.
5. Where a shorter-acting amylin comparator is needed, pramlintide is the customary reference.

What has been studied

Cagrilintide papers focus on the calcitonin receptor and its RAMP partners, satiety signalling in the hypothalamus and area postrema, gastric-emptying readouts in animal models, and studies combining it with incretin agonists. Since native amylin forms fibrils so easily, a large part of the analogue work is really chemistry: do the fibril-blocking substitutions preserve receptor activity, and how does the fatty side chain change where the peptide goes in the body?

The semaglutide literature is both bigger and different in character. It spans GLP-1 receptor binding and cAMP time-courses in transfected cells, beta-arrestin recruitment and receptor internalisation, insulin release from isolated islets and beta-cell lines, and rodent work on feeding and body composition. Clinical trial data exist for authorised prescription medicines based on semaglutide and for investigational cagrilintide products, but those trials concern regulated pharmaceutical products given with medical oversight, not research-grade material. Our weight-loss peptide research overview compares both compounds with the other options.

Matching compound to question

• For amylin receptor work, RAMP-dependent signalling or calcitonin receptor studies, use cagrilintide — semaglutide has no activity at these receptors.
• GLP-1 receptor pharmacology and incretin potency panels call for semaglutide, since cagrilintide does nothing at that receptor.
• For satiety circuitry and stomach emptying, use both in separate arms, since each pathway influences these shared endpoints through its own receptor.
• To test whether independent satiety signals are additive, use each compound alone plus a combined arm, ideally at a fixed ratio so the result can be reproduced.
• Amyloid and aggregation chemistry calls for cagrilintide as the engineered counterpoint to native amylin's fibrillation.
• If you want to add a second incretin receptor instead of a second hormone class, see semaglutide vs tirzepatide.

Differences in handling and storage

As freeze-dried powders, both are stored sealed at −20 °C, protected from light and humidity; after reconstitution they move to 2-8 °C, stay in the dark and are used up within the planned study period. For the general rules, read how to store peptides.

Chemically, however, they behave differently. Cagrilintide contains a disulfide bond, so reducing agents in the buffer will damage it, and amylin-type peptides are known aggregators: prepare solutions fresh, inspect concentrated stocks before each use, and never vortex, because the shear forces and air–liquid contact that vortexing produces are exactly what seeds aggregates. Where the assay's pH matters, a dilute buffer is usually preferred over plain water. Semaglutide's issue is adsorption: the C18 fatty chain makes it sufficiently lipophilic to bind to standard plastics at low concentration, which low-binding labware largely avoids. Both suffer from repeated freezing and thawing, so aliquoting right after reconstitution is the usual precaution for either.

Worked example with 5 mg vials

Since each compound is available as a 5 mg vial, the calculation can be done in parallel. Dissolving 5 mg in 2 mL of bacteriostatic water yields 2.5 mg/mL for either peptide. Converted to molarity, that is about 567 micromolar for cagrilintide (4409.07 g/mol) but about 608 micromolar for semaglutide (4113.58 g/mol). Nobody would notice a 7% discrepancy on the vial label, yet it shows up clearly in a dose–response fit, so record the molar concentration you actually used alongside the mg/mL you prepared. For cell-based work, dilute this stock into assay buffer just before the experiment instead of keeping dilute solutions, which lose peptide to container walls more quickly than concentrated stocks.

Checking purity and identity

Request the certificate matching each lot and look at three things: HPLC purity with the chromatogram shown, a mass-spec value in line with theory (cagrilintide 4409.07 g/mol; semaglutide 4113.58 g/mol), and a lot number identical to the one on your vial. Cagrilintide requires one extra check that incretin analogues do not: evidence that it is in the ring-closed, oxidised form with the disulfide formed, not the open reduced chain — a difference of only about 2 Da but a large one in receptor behaviour. For both peptides the weighed mass includes counter-ions and residual moisture, so it overstates the actual peptide content; base comparisons on a measured concentration rather than the label.

Regulatory framing

Semaglutide is the active substance in authorised prescription medicines, whereas cagrilintide has so far been tested in investigational clinical studies. Whatever human data exist belong to those regulated products and the supervised settings in which they were generated; they say nothing about research-grade reagents.